Investor Presentaiton

Oncology Opdivo Opdualag TIGIT Bispecific DGK Inhibitor AR LDD AR LDD: Opportunity to move into pivotal studies in next 18 months Phase 1 data across mutant/wildtype subgroups to be presented at a medical congress in 2024 + ФГ Next Steps Discuss pivotal study options with health authorities 艮 Consider expanding into hormone sensitive indications Δ Explore novel combinations to potentially enhance efficacy or synergy Ill Bristol Myers Squibb™ Not for Product Promotional Use 108

View entire presentation